Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC

Clinical trial NCT07561983 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07561983
Sponsor: Sichuan Cancer Hospital and Research Institute
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Unresectable Stage III Non-small Cell Lung Cancer Tislelizumab Chemotherapy Chemoembolization, Therapeutic Conversion Therapy

Start date: 2026-05-01
Primary completion: 2028-10-31
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.